Search

Your search keyword '"Campilho, Fernando"' showing total 45 results
Start Over Author "Campilho, Fernando"
45 results on '"Campilho, Fernando"'

2. Phase I/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease

Author

Soares, Maria VD, primary, Escamilla Gomez, Virginia, additional, Azevedo, Rita I, additional, Pereira, Paulo N.G., additional, Velázquez, Teresa Caballero, additional, Garcia-Calderón, Clara B., additional, Tharmaratnam, Kukatharmini, additional, Cabral, Inês A, additional, Ribeiro, Ana C, additional, Mendes, Laura, additional, Juncal, Clara, additional, Roncon, Susana, additional, Pais, Ana Teresa, additional, Alho, Ana C, additional, Rodriguez Gil, Alfonso, additional, Espada, Eduardo L, additional, Rodrigues, Anabela, additional, Garção, Ana, additional, Yaspo, Marie-Laure, additional, Warnatz, Hans-Jörg, additional, Lehrach, Hans, additional, Barbosa-Morais, Nuno L., additional, Quintas, Ana Miguel, additional, Palmela, Paulo, additional, Caldas, Cecilia, additional, Ferreira, Rosa, additional, Leite, Luis, additional, Martins, Carlos, additional, Lourenço, Fernanda, additional, Moreno, Raúl, additional, Raposo, João, additional, Campilho, Fernando, additional, Cheyne, Christopher Paul, additional, Garcia-Fiñana, Marta, additional, Campos, António, additional, Baron, Frédéric, additional, Arpinati, Mario, additional, Edinger, Matthias, additional, Ritz, Jerome, additional, Vaz, Carlos Pinho, additional, Perez-Simon, Jose A., additional, and Lacerda, Joao F, additional

Published
2022
Full Text
View/download PDF

4. IL-10 overexpression predisposes to invasive aspergillosis by suppressing antifungal immunity

Author

Cunha, Cristina, Gonçalves, Samuel M., Duarte-Oliveira, Cláudio, Leite, Luís, Lagrou, Katrien, Marques, António, Lupiañez, Carmen B., Mesquita, Inês, Gaifem, Joana, Barbosa, Ana Margarida, Vaz, Carlos Pinho, Branca, Rosa, Campilho, Fernando, Freitas, Fátima, Ligeiro, Dário, Lass-Flörl, Cornelia, Löffler, Jürgen, Jurado, Manuel, Saraiva, Margarida, Kurzai, Oliver, Rodrigues, Fernando, Castro, António G., Silvestre, Ricardo, Sainz, Juan, Maertens, Johan A., Torrado, Egídio, Jacobsen, Ilse D., Lacerda, João F., Campos, António, Jr, and Carvalho, Agostinho

Published
2017
Full Text
View/download PDF

5. Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis

Author

Gonçalves, Samuel M., primary, Antunes, Daniela, additional, Leite, Luis, additional, Mercier, Toine, additional, Horst, Rob ter, additional, Vieira, Joana, additional, Espada, Eduardo, additional, Pinho Vaz, Carlos, additional, Branca, Rosa, additional, Campilho, Fernando, additional, Freitas, Fátima, additional, Ligeiro, Dário, additional, Marques, António, additional, van de Veerdonk, Frank L., additional, Joosten, Leo A. B., additional, Lagrou, Katrien, additional, Maertens, Johan, additional, Netea, Mihai G., additional, Lacerda, João F., additional, Campos, António, additional, Cunha, Cristina, additional, and Carvalho, Agostinho, additional

Published
2021
Full Text
View/download PDF

7. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author

Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, Janakiram, Murali, Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, and Janakiram, Murali

Published
2019

8. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, Janakiram, Murali, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, and Janakiram, Murali

Published
2019

10. Additional file 1: of Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report

Author

Cerveira, Nuno, Ferreira, Rosa, Bizarro, Susana, CecĂ­Lia Correia, Torres, Lurdes, Lisboa, Susana, Vieira, Joana, Santos, Rui, Campilho, Fernando, Vaz, Carlos Pinho, LuĂ­S Leite, Teixeira, Manuel, and AntĂłnio Campos

Abstract

Table S1. Clinical and laboratory data of the patient. (DOCX 17 kb)

Published
2018
Full Text
View/download PDF

11. PTX3 Polymorphisms Influence Cytomegalovirus Reactivation After Stem-Cell Transplantation

Author

Campos, Cláudia F., primary, Leite, Luís, additional, Pereira, Paulo, additional, Vaz, Carlos Pinho, additional, Branca, Rosa, additional, Campilho, Fernando, additional, Freitas, Fátima, additional, Ligeiro, Dário, additional, Marques, António, additional, Torrado, Egídio, additional, Silvestre, Ricardo, additional, Lacerda, João F., additional, Campos Jr., António, additional, Cunha, Cristina, additional, and Carvalho, Agostinho, additional

Published
2019
Full Text
View/download PDF

12. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author

Dimopoulos, Meletios A, primary, Gay, Francesca, additional, Schjesvold, Fredrik, additional, Beksac, Meral, additional, Hajek, Roman, additional, Weisel, Katja Christina, additional, Goldschmidt, Hartmut, additional, Maisnar, Vladimir, additional, Moreau, Philippe, additional, Min, Chang Ki, additional, Pluta, Agnieszka, additional, Chng, Wee-Joo, additional, Kaiser, Martin, additional, Zweegman, Sonja, additional, Mateos, Maria-Victoria, additional, Spencer, Andrew, additional, Iida, Shinsuke, additional, Morgan, Gareth, additional, Suryanarayan, Kaveri, additional, Teng, Zhaoyang, additional, Skacel, Tomas, additional, Palumbo, Antonio, additional, Dash, Ajeeta B, additional, Gupta, Neeraj, additional, Labotka, Richard, additional, Rajkumar, S Vincent, additional, Bar, Daniel, additional, Basso, Alfredo, additional, Fantl, Dorotea, additional, He, Simon, additional, Horvath, Neomi, additional, Lee, Cindy, additional, Rowlings, Phillip, additional, Taylor, Kerry, additional, Cochrane, Tara, additional, Kwok, Fiona, additional, Ramanathan, Sundreswran, additional, Agis, Hermine, additional, Zojer, Niklas, additional, Kentos, Alain, additional, Offner, Fritz, additional, Van Droogenbroeck, Jan, additional, Wu, Ka Lung, additional, Maiolino, Angelo, additional, Martinez, Gracia, additional, Zanella, Karla, additional, Capra, Marcelo, additional, Araújo, Sérgio, additional, Gregora, Evzen, additional, Pour, Ludek, additional, Scudla, Vlastimil, additional, Spicka, Ivan, additional, Abildgaard, Niels, additional, Andersen, Niels, additional, Jensen, Bo Amdi, additional, Helleberg, Carsten, additional, Plesner, Torben, additional, Salomo, Morten, additional, Svirskaite, Asta, additional, Delarue, Richard, additional, Blau, Igor, additional, Schieferdecker, Aneta, additional, Teleanu, Veronica, additional, Munder, Markus, additional, Röllig, Christoph, additional, Salwender, Han-Juergen, additional, Fuhrmann, Stephan, additional, Weisel, Katja, additional, Duerig, Jan, additional, Zeis, Matthias, additional, Klein, Stefan, additional, Reimer, Peter, additional, Schmidt, Christian, additional, Scheid, Christof, additional, Mayer, Karin, additional, Hoffmann, Martin, additional, Sosada, Markus, additional, Dimopoulos, Athanasios, additional, Delimpasi, Sosana, additional, Kyrtsonis, Mary-Christine, additional, Anagnostopoulos, Achilleas, additional, Nagy, Zsolt, additional, Illés, Árpád, additional, Egyed, Miklós, additional, Borbényi, Zita, additional, Mikala, Gabor, additional, Dally, Najib, additional, Horowitz, Netanel, additional, Gutwein, Odit, additional, Nemets, Anatoly, additional, Vaxman, Iuliana, additional, Shvetz, Olga, additional, Trestman, Svetlana, additional, Ruchlemer, Rosa, additional, Nagler, Arnon, additional, Tadmor, Tamar, additional, Rouvio, Ory, additional, Preis, Meir, additional, Cavo, Michele, additional, De Rosa, Luca, additional, Musto, Pellegrino, additional, Cafro, Anna, additional, Tosi, Patrizia, additional, Offidani, Massimo, additional, Corso, Alessandro, additional, Rossi, Giuseppe, additional, Liberati, Anna Marina, additional, Bosi, Alberto, additional, Suzuki, Kenshi, additional, Nakaseko, Chiaki, additional, Ishikawa, Takayuki, additional, Matsumoto, Morio, additional, Nagai, Hirokazu, additional, Sunami, Kazutaka, additional, Chou, Takaaki, additional, Akashi, Koichi, additional, Takezako, Naoki, additional, Hagiwara, Shotaro, additional, Eom, Hyeon Seok, additional, Jo, Deog-Yeon, additional, Kim, Jin Seok, additional, Lee, Jae Hoon, additional, Yoon, Sung Soo, additional, Yoon, Dok Hyun, additional, Kim, Kihyun, additional, Levin, Mark-David, additional, Vellenga, Edo, additional, Minnema, Monique, additional, Waage, Anders, additional, Haukås, Einar, additional, Grosicki, Sebastian, additional, Pluta, Andrzej, additional, Robak, Tadeusz, additional, Marques, Herlander, additional, Bergantim, Rui, additional, Campilho, Fernando, additional, Chng, Wee Joo, additional, Goh, Yeow Tee, additional, McDonald, Andrew, additional, Rapoport, Bernado, additional, Álvarez Rivas, Miguel Angel, additional, De Arriba de La Fuente, Felipe, additional, González Montes, Yolanda, additional, Martin Sanchez, Jesus, additional, Mateos, Maria Victoria, additional, Oriol Rocafiguera, Albert, additional, Rosinol, Laura, additional, San Miguel, Jesús, additional, Pérez de Oteyza, Jaime, additional, Encinas, Cristina, additional, Alegre-Amor, Adrian, additional, López-Guía, Ana, additional, Axelsson, Per, additional, Carlson, Kristina, additional, Stromberg, Olga, additional, Hansson, Markus, additional, Hveding Blimark, Cecile, additional, Mueller, Rouven, additional, Chen, Chih-Cheng, additional, Liu, Ta-Chih, additional, Huang, Shang-Yi, additional, Wang, Po-Nan, additional, Na Nakorn, Thanyaphong, additional, Prayongratana, Kannadit, additional, Unal, Ali, additional, Goker, Hakan, additional, Sonmez, Mehmet, additional, Korenkova, Sybiryna, additional, Chaidos, Aristeidis, additional, Oakervee, Heather, additional, Sati, Hamdi, additional, Benjamin, Reuben, additional, Wechalekar, Ashutosh, additional, Garg, Mamta, additional, Ramasamy, Karthik, additional, Cook, Gordon, additional, Chantry, Andrew, additional, Jenner, Matthew, additional, Buadi, Francis, additional, Berryman, Robert, additional, and Janakiram, Murali, additional

Published
2019
Full Text
View/download PDF

14. Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report

Author

Cerveira, Nuno, primary, Ferreira, Rosa Branca, additional, Bizarro, Susana, additional, Correia, Cecília, additional, Torres, Lurdes, additional, Lisboa, Susana, additional, Vieira, Joana, additional, Santos, Rui, additional, Campilho, Fernando, additional, Pinho Vaz, Carlos, additional, Leite, Luís, additional, Teixeira, Manuel R., additional, and Campos, António, additional

Published
2018
Full Text
View/download PDF

15. Minimal change nephrotic syndrome after stem cell transplantation: a case report and literature review

Author

Silva Sandra, Maximino José, Henrique Rui, Paiva Ana, Baldaia Jorge, Campilho Fernando, Pimentel Pedro, and Loureiro Alfredo

Subjects
Medicine
Abstract

Abstract Graft-versus-host disease is one of the most frequent complications occurring after haematopoietic stem cell transplantation. Recently, renal involvement has been described as a manifestation of chronic graft-versus-host disease. Immunosuppression seems to play a major role: clinical disease is triggered by its tapering and resolution is achieved with the resumption of the immunosuppressive therapy. Prognosis is apparently favourable, but long term follow up data are lacking. We report a case of a 53-year-old man who developed nephrotic syndrome 142 days after allogeneic stem cell transplantation for acute myeloid leukaemia. Onset of nephrotic syndrome occurred after reduction of immunosuppressants and was accompanied by manifestations of chronic graft-versus-host disease. Histological examination of the kidney was consistent with Minimal Change Disease. After treatment with prednisolone and mycophenolate mofetil he had complete remission of proteinuria and improvement of graft-versus-host disease. Eighteen months after transplantation the patient keeps haematological remission and normal renal function, without proteinuria. Since patients with chronic graft-versus-host disease might be considered at risk for development of nephrotic syndrome, careful monitoring of renal parameters, namely proteinuria, is advisable.

Published
2007
Full Text
View/download PDF

16. Post‑transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012

Author

Marinho‑Dias, Joana, primary, Lobo, Jo�o, additional, Henrique, Rui, additional, Baldaque, In�s, additional, Pinho‑Vaz, Carlos, additional, Regadas, Lu�sa, additional, Branca, Rosa, additional, Campilho, Fernando, additional, Jr, Ant�nio, additional, Medeiros, Rui, additional, and Sousa, Hugo, additional

Published
2018
Full Text
View/download PDF

19. TREG and Tcon Dynamics after Allo-HSCT: Cgvhd Is Associated to Decreased NaïVe and Stem Cell Memory Subsets with a Concomitant Increase in Terminally Differentiated T Cell Subsets

Author

Soares, Maria V.D., primary, Azevedo, Rita I, additional, Ferreira, Ines A, additional, Bucar, Sara Ventura, additional, Alho, Ana Cristina, additional, Espada, Eduardo L, additional, Clara, Juncal, additional, Camacho, Nadia, additional, Martins, Carlos M., additional, Carmo, José A, additional, Lourenço, Fernanda, additional, Moreno, Raul, additional, Vaz, Carlos, additional, Campos, Antonio M., additional, Campilho, Fernando, additional, Ferreira, Rosa, additional, Ritz, Jerome, additional, and Lacerda, Joao F, additional

Published
2016
Full Text
View/download PDF

20. Association of Epstein-Barr virus infection with allogeneic hematopoietic stem cell transplantation in patients in Portugal.

Author

Marinho-Dias, Joana, Baldaque, Inês, Pinho-Vaz, Carlos, Leite, Luís, Branca, Rosa, Campilho, Fernando, Campos, António, Medeiros, Rui, and Sousa, Hugo

Subjects
EPSTEIN-Barr virus, EPSTEIN-Barr virus diseases, HOMOGRAFTS, HEMATOPOIETIC stem cell transplantation, GLOBULINS, LYMPHOPROLIFERATIVE disorders
Abstract

The identification of patients at higher risk of developing Epstein-Barr virus (EBV) infection in hematopoietic stem cell transplants (HSCT) is useful for the prevention of EBV-associated diseases A prospective observational study was developed that included 40 patients (27 male and 13 females, with mean age of 32.2±1.5 years old) undergoing allogeneic-HSCT between January and December 2015. EBV was examined in whole blood samples collected during routine procedures at day (D)+30, D +60, +90, D+120, D+150 and D+180 post-transplant. EBV was detected, at least once during the follow-up period in 70.0% of our patients. Results indicated that patients with unrelated donors had increased risk of developing EBV infection at D+60 and D+150 (OR=3.9, P=0.058; OR=8.0, P=0.043; respectively). Moreover, myeloablative conditioning (OR=4.3, P=0.052), anti-thymocyte globulin use (OR=12.0, P=0.030) and graft-vs.-host disease (OR=6.7, P=0.032) were associated with EBV infection at D+60, D+150 and D+90, respectively. In our series, none of these patients developed post-transplant lymphoproliferative disease. To the best of our knowledge, the present study is the first study to report EBV infection in patients undergoing aHSCT from Portugal. The study revealed that EBV infection is associated with different factors. These findings provide evidence towards the identification of high-risk patients for EBV-infection and associated disease. [ABSTRACT FROM AUTHOR]

Published
2019

21. Visceral Leishmaniasis: A Differential Diagnosis to Remember after Bone Marrow Transplantation

Author

Dantas Brito, Margarida, Campilho, Fernando, Branca, Rosa, Pinho Vaz, Carlos, Silva, Cristina, Sousa, Teresa, Mendes, Carlos, and Campos, António

Subjects
Article Subject, hemic and lymphatic diseases
Abstract

Leishmania infection in immunocompromised hosts is reported in the literature, mostly concerning human immunodeficiency virus infected patients. It is not well characterized in the context of stem cell transplantation. We report a rare case clinical case of visceral leishmaniasis after allogeneic bone marrow transplantation. A 50-year-old Caucasian male was referred to allogeneic bone marrow transplantation with a high-risk acute lymphoblastic B leukemia in first complete remission. Allogeneic SCT was performed with peripheral blood stem cells from an unrelated Portuguese matched donor. In the following months, patient developed mild fluctuating cytopenias, mostly thrombocytopenia (between 60 and 80∗109/L). The only significant complaint was intermittent tiredness. The common causes for thrombocytopenia in this setting were excluded—no evidence of graft versus host disease, no signs of viral or bacterial infection, and no signs of relapsed disease/dysplastic changes. The bone marrow smear performed 12 months after transplantation revealed an unsuspected diagnosis: a massive bone marrow infiltration with amastigotes.

Published
2014
Full Text
View/download PDF

25. Rhizomucor and Scedosporium Infection Post Hematopoietic Stem-Cell Transplant

Author

Marques, Dânia Sofia, Pinho Vaz, Carlos, Branca, Rosa, Campilho, Fernando, Lamelas, Catarina, Afonso, Luis Pedro, Jacome, Manuel, Breda, Eduardo, Monteiro, Eurico, and Campos Júnior, António

Subjects
Article Subject
Abstract

Hematopoietic stem-cell transplant recipients are at increased risk of developing invasive fungal infections. This is a major cause of morbidity and mortality. We report a case of a 17-year-old male patient diagnosed with severe idiopathic acquired aplastic anemia who developed fungal pneumonitis due to Rhizomucor sp. and rhinoencephalitis due to Scedosporium apiospermum 6 and 8 months after undergoing allogeneic hematopoietic stem-cell transplant from an HLA-matched unrelated donor. Discussion highlights risk factors for invasive fungal infections (i.e., mucormycosis and scedosporiosis), its clinical features, and the factors that must be taken into account to successfully treat them (early diagnosis, correction of predisposing factors, aggressive surgical debridement, and antifungal and adjunctive therapies).

Published
2011
Full Text
View/download PDF

26. Transfusion Requirements After Allogeneic Hematopoietic Stem Cell Transplantation

Author

Amado,Fátima, Bini-Antunes,Marika, Santos,Luísa, Rosales,Maria, Campilho,Fernando, Pimentel,Pedro, and Carvalhais,Alzira

Subjects
transfusões, concentrados de eritrócitos, transplante alogénico, compatibilidade, progenitores hematopoiéticos, hematopoietic, stem cell transplantation, concentrados de plaquetas, transfusion
Abstract

O objectivo deste estudo foi avaliar, nos doentes submetidos a transplante de progenitores hematopoiéticos (TPH) alogénico, o efeito do regime de condicionamento, da fonte de progenitores, das compatibilidades ABO e HLA e do parentesco do par dador/receptor no consumo transfusional no período pós-transplante. Avaliamos retrospectivamente os doentes submetidos ao primeiro alotransplante no período compreendido entre Janeiro 2003 e Setembro 2005. Consultaram-se as bases de dados do Departamento de Imuno-Hemoterapia. A análise estatística foi realizada com recurso ao programa SPSS®. No período considerado realizaram-se 97 alotransplantes, dos quais 94 foram primeiros transplantes e elegíveis para o estudo (43,6% sexo feminino e 56,4% sexo masculino, mediana de idades de 38,5 anos, limites 6 meses-66 anos). Foram submetidos a um regime de condicionamento mieloablativo 50 doentes (53,2%) e a condicionamento de intensidade reduzida (CIR) 44 doentes (46,8%). Relativamente à fonte de progenitores utilizados, em 88,3 % dos doentes (n=83) foram células progenitoras hematopoiéticas perifericas (CPHP), em 7,5% (n=7) medula óssea (MO) e em 4,2% (n=4) sangue de cordão umbilical (SCU). No que respeita ao sistema HLA e ao parentesco, 95,7 % (n=90) dos transplantes foram HLA compatíveis e 87,2% (n=82) foram de dador relacionado. Relativamente ao sistema ABO do par dador/receptor, 27,6% (n=26) dos casos apresentavam incompatibilidade maior, 10,6% (n=10) menor e 57,4% (n=54) eram compatíveis. Não observamos diferenças estatisticamente significativas nas medianas de episódios transfusionais de concentrados de eritrócitos (CE) e de concentrados de plaquetas (CP) no que se refere a incompatibilidade ABO (p>0,05). Nos doentes transplantados com CPHP observamos uma tendência para um menor consumo transfusional de CP relativamente aos transplantados com SCU e MO. No entanto, o teste estatístico aplicado não mostrou um resultado significativo para os CE (p=0,054), provavelmente por causa do pequeno número de doentes transplantados com SCU e MO na população estudada. Os CIR foram associados a um menor consumo de CP (p< 0,0001). Não observamos diferenças significativas no número de episódios transfusionais de CE e CP no que se refere a incompatibilidade HLA e ao parentesco no par dador/receptor (p>0,05). We retrospectively studied all the first allogeneic hematopoietic stem cell transplantation (HSCT) performed in our Centre between January 2003 and September 2005. We evaluated the influence of haematopoietic stem cell source, ABO and HLA compatibility and relationship in donor/recipient pair as well as conditioning regimen (myeloablative versus reduced intensity) on transfusion requirements. We analysed patients’ transfusion requirements during a 100 days period after transplantation. The medians of red blood cells (RBC) and platelets (PL) transfusion episodes (TE) were considered as an estimative of the transfusion requirements. We performed a statistical analysis recurring to the SPSS® software. Ninety four patients (43.6% women, 56.4% men), median age 38.5 years (range 6 months-66 years), were submitted to a first HSCT. In 88.3% (n=83) of patients the haematopoietic stem cell source was peripheral blood, in 7.4% (n=7) bone marrow (BM) and in 4.3% (n=4) umbilical cord blood (UCB). In 95.7% of cases there was HLA compatibility and in 87.2% a relationship between the donor and the recipient. We observed a major ABO incompatibility in 27.6% (n=26) of cases and minor in 10.6% (n=10). In 57.4% (n=54) of transplants there was ABO compatibility. Conditioning regimen was myeloablative and of reduced intensity in 53.2% (n=50) and in 46.8% (n=44) of patients, respectively. We observed that ABO compatibility had not a major impact on transfusion requirements (p>0.05). Patients transplanted with peripheral blood progenitor cells (PBPC) showed a tendency to a lesser PL transfusion need when compared to patients transplanted with UCB and BM but the test applied was not significant for RBC, probably because of the low number UCB and BM transplants considered in this study. Reduced intensity conditioning was associated with a reduced PL transfusion need (p< 0.0001). In unrelated transplants and HLA mismatches the transfusion episodes after transplantation were not higher when compared to related and HLA compatible transplants (p>0.05).

Published
2007

27. Colheita de células progenitoras hematopoiéticas periféricas em doentes pediátricos

Author

Bini-Antunes, Marika, Roncon, Susana, Campilho, Fernando, Barbosa, Isabel, Leal, Helena, Ávila, Alcina, Ferreira, Sara, Campos, António, Vaz, Carlos Pinho, Ferreira, Rosa Branca, Pimentel, Pedro, Norton, Lucília, and Carvalhais, Alzira

Subjects
progenitor stern cell, children, aférese, antologous transplantation, progenitores hematopoiéticos, transplante autólogo, crianças
Abstract

A evolução das técnicas de aférese tem permitido a colheita de células progenitoras hematopoiéticas periféricas (CPHP) em crianças candidatas a autotransplante. Neste trabalho analisamos retrospectivamente 71 crianças (37 de sexo masculino e 34 de sexo feminino) propostas para autotransplante no IPO-Porto entre Dezembro 1995 e Setembro 2005. Os doentes tinham uma mediana de 10 anos de idade e um peso mediano de 29 kg. Apresentavam os seguintes diagnósticos: neuroblastoma 20, doença de Hodgkin 13, leucemia mielóide aguda 9, leucemia linfoblastica aguda 8, linfoma não Hodgkin 6, sarcoma de Ewing 5, outros diagnósticos 10. Todos os doentes foram tratados com quimioterapia antes da primeira mobilização (mediana de 2 protocolos) e em 9 deles também foi efectuada radioterapia. As crianças foram mobilizadas com G-CSF com uma dose diária mediana de 11,1 µg/kg (mínimo 5-máximo 20) na primeira mobilização e 18.1 µg/kg (mínimo 6, máximo 25-21) na segunda mobilização. Iniciamos as colheitas ao 5º dia de mobilização e uma hora após a injecção de G-CSF. Foram realizadas, no máximo, três aféreses por mobilização. Em 22 crianças (28,2%) foi necessária uma segunda mobilização e em 4 (5,6%) uma terceira para atingir uma dose alvo de 2x10(6)/kg células CD34+. Foi efectuado priming com eritrócitos em 32 doentes (45%). Em cada aférese foram processadas uma mediana de 4 volemias, sendo o tempo mediano de duração de cada procedimento de 141 minutos. A mediana do débito sanguíneo mantido foi de 59 ml/min. Uma mediana de 0,94x10(6)/kg e 0,80x10(6)/kg células CD34+ foi colhida por aférese, na primeira e na segunda mobilização, respectivamente. Encontramos uma correlação estatisticamente significativa entre o número de células CD34+ no sangue periférico pré aférese e na colheita (coeficiente de Pearson 0,834, p

Published
2006

35. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation

Author

Moscardó, Federico, primary, Urbano-Ispizua, Álvaro, additional, Sanz, Guillermo F, additional, Brunet, Salut, additional, Caballero, Dolores, additional, Vallejo, Carlos, additional, Solano, Carlos, additional, Pimentel, Pedro, additional, Pérez de Oteyza, Jaime, additional, Ferrá, Christelle, additional, Dı́ez-Martı́n, José L, additional, Zuazu, Javier, additional, Espigado, Ildefonso, additional, Campilho, Fernando, additional, Arbona, Cristina, additional, Moraleda, José M, additional, Mateos, Marı́a V, additional, Sierra, Jordi, additional, Talarn, Carmen, additional, and Sanz, Miguel A, additional

Published
2003
Full Text
View/download PDF

36. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings

Author

Urbano-Ispizua, Alvaro, primary, Rozman, Ciril, additional, Pimentel, Pedro, additional, Solano, Carlos, additional, de la Rubia, Javier, additional, Brunet, Salut, additional, Pérez-Oteyza, Jaime, additional, Ferrá, Christelle, additional, Zuazu, Javier, additional, Caballero, Dolores, additional, Bargay, Joan, additional, Carvalhais, Alzira, additional, Dı́ez, Jose Luis, additional, Espigado, Ildefonso, additional, Alegre, Adrián, additional, Rovira, Montserrat, additional, Campilho, Fernando, additional, Odriozola, Jesús, additional, Sanz, Miguel Angel, additional, Sierra, Jordi, additional, Garcı́a-Conde, Javier, additional, and Montserrat, Emili, additional

Published
2002
Full Text
View/download PDF

37. ANEMIA DE FANCONI.

Author

PORTO, Beatriz, SOUSA, Rosa, PONTE, Filipa, TORGAL, Ana, CAMPILHO, Fernando, CAMPOS, António, GONÇALVES, Cristina, and BARBOT, José

Published
2011

38. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+selected blood cells from HLA-identical siblings

Author

Urbano-Ispizua, Alvaro, Rozman, Ciril, Pimentel, Pedro, Solano, Carlos, de la Rubia, Javier, Brunet, Salut, Pérez-Oteyza, Jaime, Ferrá, Christelle, Zuazu, Javier, Caballero, Dolores, Bargay, Joan, Carvalhais, Alzira, Dı́ez, Jose Luis, Espigado, Ildefonso, Alegre, Adrián, Rovira, Montserrat, Campilho, Fernando, Odriozola, Jesús, Sanz, Miguel Angel, Sierra, Jordi, Garcı́a-Conde, Javier, and Montserrat, Emili

Abstract

A study on 315 patients undergoing transplantation with CD34+selected blood cells from HLA-identical siblings was performed to determine risk factors for acute GVHD (aGVHD). Recipients of a dose of CD34+cells (× 106/kg) of 2 or less, more than 2 to 4, and more than 4 had a cumulative incidence of aGVHD grades I-IV of 21%, 35%, and 43%, respectively (log-rankP= .01); similarly, recipients of a dose of CD3+cells (× 106/kg) of 0.05 or less, more than 0.05 to 0.1, and more than 0.1 had a cumulative incidence of aGVHD grades I-IV of 18%, 35%, and 44%, respectively (log-rankP= .007). Using a Cox regression model, 4 independent factors for aGVHD I-IV were identified: increased CD34+cell dose (P= .02), increased CD3+cell dose (P= .02), female patients (P= .01), and higher patient age (> 42 years) (P= .007). This study shows, for the first time in T-cell–depleted transplantations, a positive correlation between the number of CD34+cells and aGVHD and, also, that the number of CD3+cells necessary to initiate aGVHD is lower than previously reported.

Published
2002
Full Text
View/download PDF

39. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings

Author

Urbano-Ispizua, Alvaro, Rozman, Ciril, Pimentel, Pedro, Solano, Carlos, de la Rubia, Javier, Brunet, Salut, Pérez-Oteiza, Jaime, Ferrá, Christelle, Zuazu, Javier, Caballero, Dolores, Carvalhais, Alzira, Dı́ez, Jose Luis, Espigado, Ildefonso, Martı́nez, Carmen, Campilho, Fernando, Sanz, Miguel Angel, Sierra, Jorge, Garcı́a-Conde, Javier, and Montserrat, Emilio

Abstract

This study analyzed the characteristics of 257 HLA-identical sibling transplants of granulocyte colony-stimulating factor–mobilized peripheral blood progenitor cells depleted of T cells by CD34+ positive selection (allo-PBT/CD34+) for their effect on the incidence of graft failure. Twenty-four patients developed graft failure (actuarial probability, 11%; 95% confidence interval, 7.1-14.9). Prognostic factors considered were sex and age of donor and recipient, donor-recipient blood group compatibility, diagnosis, disease status at transplant, conditioning regimen, cytomegalovirus serology, number of CD34+ and CD3+ cells infused, and cryopreservation. The major factor associated with graft failure was the number of CD3+ cells in the inoculum. Twenty-three of 155 patients receiving a T-cell dose in the graft less than or equal to 0.2 × 106/kg experienced graft failure, compared with only one of 102 patients receiving more than 0.2 × 106/kg (actuarial probability 18% vs 1%, respectively; P = .0001). The actuarial probability of graft failure progressively increased as the number of CD3+ cells in the graft decreased, which was determined by grouping the number of CD3+ cells in quartiles (log-rankP = .03; log-rank for trend P = .003). In the multivariate analysis by the proportional hazard method, 2 covariates entered into regression at a significant level: CD3+ cells less than or equal to 0.2 × 106/kg (risk ratio = 17;P < .0001), and patients with chronic myelogenous leukemia (CML) conditioned with busulphan-based regimens (risk ratio = 4.8; P = .001). From these results it appears that the number of CD3+ cells in the inoculum—with a threshold of 0.2 × 106/kg or less—is the most critical factor in maintaining a sustained engraftment in allo-PBT/CD34+ from HLA-identical siblings. In addition, for patients with CML receiving 0.2 × 106/kg or less CD3+ cells, total body irradiation might be better than busulphan-based regimens.

Published
2001
Full Text
View/download PDF

40. The number of donor CD3+cells is the most important factor for graft failure after allogeneic transplantation of CD34+selected cells from peripheral blood from HLA-identical siblings

Author

Urbano-Ispizua, Alvaro, Rozman, Ciril, Pimentel, Pedro, Solano, Carlos, de la Rubia, Javier, Brunet, Salut, Pérez-Oteiza, Jaime, Ferrá, Christelle, Zuazu, Javier, Caballero, Dolores, Carvalhais, Alzira, Dı́ez, Jose Luis, Espigado, Ildefonso, Martı́nez, Carmen, Campilho, Fernando, Sanz, Miguel Angel, Sierra, Jorge, Garcı́a-Conde, Javier, and Montserrat, Emilio

Abstract

This study analyzed the characteristics of 257 HLA-identical sibling transplants of granulocyte colony-stimulating factor–mobilized peripheral blood progenitor cells depleted of T cells by CD34+positive selection (allo-PBT/CD34+) for their effect on the incidence of graft failure. Twenty-four patients developed graft failure (actuarial probability, 11%; 95% confidence interval, 7.1-14.9). Prognostic factors considered were sex and age of donor and recipient, donor-recipient blood group compatibility, diagnosis, disease status at transplant, conditioning regimen, cytomegalovirus serology, number of CD34+and CD3+cells infused, and cryopreservation. The major factor associated with graft failure was the number of CD3+cells in the inoculum. Twenty-three of 155 patients receiving a T-cell dose in the graft less than or equal to 0.2 × 106/kg experienced graft failure, compared with only one of 102 patients receiving more than 0.2 × 106/kg (actuarial probability 18% vs 1%, respectively; P= .0001). The actuarial probability of graft failure progressively increased as the number of CD3+cells in the graft decreased, which was determined by grouping the number of CD3+cells in quartiles (log-rankP= .03; log-rank for trend P= .003). In the multivariate analysis by the proportional hazard method, 2 covariates entered into regression at a significant level: CD3+cells less than or equal to 0.2 × 106/kg (risk ratio = 17;P< .0001), and patients with chronic myelogenous leukemia (CML) conditioned with busulphan-based regimens (risk ratio = 4.8; P= .001). From these results it appears that the number of CD3+cells in the inoculum—with a threshold of 0.2 × 106/kg or less—is the most critical factor in maintaining a sustained engraftment in allo-PBT/CD34+from HLA-identical siblings. In addition, for patients with CML receiving 0.2 × 106/kg or less CD3+cells, total body irradiation might be better than busulphan-based regimens.

Published
2001
Full Text
View/download PDF

41. Visceral Leishmaniasis: A Differential Diagnosis to Remember after Bone Marrow Transplantation.

Author

Brito, Margarida Dantas, Campilho, Fernando, Branca, Rosa, Vaz, Carlos Pinho, Silva, Cristina, Sousa, Teresa, Mendes, Carlos, and Campos, António

Subjects
*VISCERAL leishmaniasis, *BONE marrow transplantation, *HIV-positive persons, *LYMPHOBLASTIC leukemia, *AMASTIGOTES
Abstract

Leishmania infection in immunocompromised hosts is reported in the literature, mostly concerning human immunodeficiency virus infected patients. It is not well characterized in the context of stem cell transplantation. We report a rare case clinical case of visceral leishmaniasis after allogeneic bone marrow transplantation. A 50-year-old Caucasian male was referred to allogeneic bone marrow transplantation with a high-risk acute lymphoblastic B leukemia in first complete remission. Allogeneic SCT was performed with peripheral blood stem cells from an unrelated Portuguese matched donor. In the following months, patient developed mild fluctuating cytopenias, mostly thrombocytopenia (between 60 and 80*109/L). The only significant complaint was intermittent tiredness. The common causes for thrombocytopenia in this setting were excluded--no evidence of graft versus host disease, no signs of viral or bacterial infection, and no signs of relapsed disease/dysplastic changes. The bone marrow smear performed 12 months after transplantation revealed an unsuspected diagnosis: a massive bone marrow infiltration with amastigotes. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

42. Increased Naive, Stem Cell Memory and Terminally Differentiated CD8+ T Cells in Chronic Graft VersusHost Disease

Author

Soares, Maria V, Azevedo, Rita I, Ferreira, Inês A, Sara, Bucar Ventura, Ligeiro, Dario, Ribeiro, Ana C, Pereira, Paulo N.G., Alho, Ana C, Espada, Eduardo L, Juncal, Clara, Camacho, Nádia, Martins, Carlos M, Carmo, José A, Lourenço, Fernanda, Moreno, Raul, Vaz, Carlos, Campos, António, Campilho, Fernando, Ferreira, Rosa, Ritz, Jerome, and Lacerda, Joao F

Abstract

BACKGROUND AND AIMS

Published
2017
Full Text
View/download PDF

43. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation

Author

Moscardó, Federico, Urbano-Ispizua, Álvaro, Sanz, Guillermo F., Brunet, Salut, Caballero, Dolores, Vallejo, Carlos, Solano, Carlos, Pimentel, Pedro, Pérez de Oteyza, Jaime, Ferrá, Christelle, Díez-Martín, José L., Zuazu, Javier, Espigado, Ildefonso, Campilho, Fernando, Arbona, Cristina, Moraleda, José M., Mateos, María V., Sierra, Jordi, Talarn, Carmen, and Sanz, Miguel A.

Subjects
*T cells, *LIVER diseases
Abstract

Objective. T-cell depletion (TCD), primarily developed to prevent graft-vs-host disease (GVHD), might reduce early liver dysfunction after allogeneic hematopoietic stem cell transplantation. However, no comparative studies have been performed to investigate this. We analyzed the influence of selection for CD34+ cells on the incidence and severity of hepatic veno-occlusive disease (VOD).Patients and Methods. Five hundred and one patients who underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical siblings were included in the present study. Two hundred and ninety patients (59%) were grafted with CD34+ positively selected grafts and 211 (41%) with nonmanipulated grafts. Their mean age was 38 years (range 17–63). All patients had hematological malignancies and 96% were conditioned with combinations either of cyclophosphamide plus total-body irradiation or of cyclophosphamide plus busulphan. Most of the patients received GVHD prophylaxis with methotrexate (MTX) or cyclosporin A.Results. Fifty-two patients (10.4%) developed VOD. VOD was more frequent in patients receiving nonmanipulated grafts (16.1% vs 6.2%; p<0.0009), in those with a Karnofsky score less than 90 (17.5% vs 7.8%; p = 0.001), and with the use of MTX for GVHD prophylaxis (14.8% vs 7%; p = 0.005). In multivariate analyses, only CD34+ positive selection (p = 0.0007) and Karnofsky score (p = 0.004) emerged as independent risk factors for VOD. The same effect was observed in the subset of patients with severe VOD.Conclusion. These findings show that CD34+ selection not only decreases the incidence of GVHD but also prevents VOD after HLA-identical sibling PBSCT. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

44. [Fanconi anemia: cytogenetic diagnosis of 40 cases].

Author

Porto B, Sousa R, Ponte F, Torgal A, Campilho F, Campos A, Gonçalves C, and Barbot J

Subjects
Adolescent, Adult, Child, Child, Preschool, Cytogenetic Analysis, Female, Humans, Infant, Male, Young Adult, Fanconi Anemia diagnosis, Fanconi Anemia genetics
Abstract

Fanconi Anemia (FA) is a rare recessive disorder clinically characterized by progressive bone marrow failure, diverse congenital malformations and increased predisposition to cancer. Given the late onset of anemia, relatively to other cytopenias, and the high variability in the phenotype, a correct clinical diagnosis is difficult, and may be delayed or even missed. This fact may be prejudicial to patients, due to the need of avoiding exposure to toxic agents, programming the transplantation of hematopoietic progenitor cells and screening of neoplasia associated with the disease. Given the high genetic variability (thirteen complementation groups have been identified, each with genes presenting several different mutations), a rapid molecular diagnosis is not possible. However, there is an urgent need for a timely and correct diagnosis, due to the early evolution of the disease towards malignancy and to the early need of finding compatible donors for future hematopoietic stem cell transplantation. Fortunately, the hypersensitivity of FA cells to the clastogenic (chromosome breaking) effect of DNA cross-linking agents, in particular to diepoxybutane (DEB), provides a unique marker for the diagnosis. At present, cytogenetic analysis for detection of DEB-induced chromosome instability is the gold-standard test for the diagnosis of FA. In the present work we present the results from the DEB induced chromosome instability studies performed in the Laboratory of Cytogenetics of ICBAS between 1992 and 2009. Blood samples from 222 patients were obtained from different hospitals mainly from the north and centre of Portugal. This population includes not only patients with clinical suspicion of FA, but also patients presented with thrombocytopenia, pancitopenia or aplastic anemia, for confirmation/exclusion of FA. Two samples of amniotic fluid were also obtained for pre-natal diagnosis. A total of 34 FA patients were diagnosed. Cytogenetic studies were also performed in blood samples from AF relatives, which allowed the diagnosis of 6 new cases, 5 of them corresponding to asymptomatic individuals. In the total population of FA patients studied, 25% belong to the gypsy ethnic group. Periodic cytogenetic studies were also performed in blood samples from AF patients post transplantation, which confirmed the elimination of the original hematopoietic DEB sensitive cells.

Published
2011

45. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis.

Author

Correia O, Delgado L, Barbosa IL, Campilho F, and Fleming-Torrinha J

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers analysis, Blister metabolism, Female, Humans, Interleukin-10 metabolism, Male, Middle Aged, Probability, Prospective Studies, Sampling Studies, Sensitivity and Specificity, Statistics, Nonparametric, Tumor Necrosis Factor-alpha metabolism, Graft vs Host Disease physiopathology, Inflammation Mediators analysis, Interleukin-10 analysis, Stevens-Johnson Syndrome physiopathology, Tumor Necrosis Factor-alpha analysis
Abstract

Background: Toxic epidermal necrolysis is a severe, usually drug-induced disease that shares clinical, histologic, and immunologic similarities with the severe forms of cutaneous acute graft-versus-host disease., Objective: Our purpose was to further characterize common immune-inflammatory pathways in these skin disorders by measurement of different cytokines., Methods: Evaluation of serum levels of interleukin 10 (IL-10), tumor necrosis factor alpha, IL-6, and soluble IL-6 receptor in the early phase of both diseases and in blister fluid of toxic epidermal necrolysis., Results: Serum levels of IL-10 and IL-6 were significantly higher in patients with toxic epidermal necrolysis (P =.0001) and acute graft-versus-host disease (P =.001) compared with those of blood donors. We found an increase in IL-6 levels in blister fluid and significantly higher levels of IL-10 (P =.018) and tumor necrosis factor alpha (P =.028) in blister fluid compared with serum in patients with toxic epidermal necrolysis., Conclusion: A similar serum cytokine profile of toxic epidermal necrolysis and acute graft-versus-host disease further emphasizes common immunologic mechanisms. The presence of inflammatory cytokines, IL-6 and tumor necrosis factor alpha, in the blister fluid of patients with toxic epidermal necrolysis is associated with significantly higher levels of IL-10, which through its down-regulatory role, may be involved in limitation of the disease extension.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results